$EW

$92.59▲ +0.6% YTD

11 SEC 13D/G filings tracked · Last updated Nov 2, 2026

Filing History

$EW - CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System…

$EW - Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features…

$EW Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features…

$EW - FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease…

$EW FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease…

$EW - Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026…

$EW Citi adds Upside 90 Day Catalyst Watch…

$EW - Edwards Lifesciences to Host Investor Event in Conjunction With TCT…

$EW - Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients…

$EW Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients…

$EW - Edwards Lifesciences Comments on TAVR National Coverage Decision…